Compare Cytokinetics Inc (CYTK) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Synchrony Financial — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Synchrony Financial trades at $73.83 (market cap $23.99B). The key difference: Synchrony Financial is far larger — about 2.8× Cytokinetics Inc's market cap, and Synchrony Financial pays a 1.84% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Synchrony Financial for 28 Days on average.
| CYTK | SYF | |
|---|---|---|
Market Cap | $8.62B | $23.99B |
Volume | 2,594,626 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $87.26 | $88.47 |
52-Week Low | $54.76 | $63.78 |
Typical Hold Time | 19 Days | 28 Days |
Enterprise Value | $8.72B | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Synchrony Financial (SYF) trades at $71.93, down 0.32% today, with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 23.4% net income margin and 22.23% ROE, trading at attractive valuations (P/E 7.56x). Recent developments include partnerships with OpenAI and Vetspire to expand AI-driven commerce and veterinary financing capabilities, while Q3 2026 earnings are scheduled for October 20, 2026.
SYF presents a compelling value opportunity with strong earnings momentum and analyst consensus target of $87.58 (22% upside). However, technical weakness and increased investing outflows in 2026 create near-term headwinds. The stock offers shareholder returns through dividends and buybacks, but faces risks from consumer credit quality and competitive payment landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
